IP Library Granted Patent US 11,584,920
Granted Patent B2
US 11,584,920 · App. 16/687,299 · Granted Feb 21, 2023

Use of enzymes with a wide pH activity range as medicaments for promoting digestion

Inventors: Marcus Wolf William Hartmann (Münster, DE); Ingo Aldag (Münster, DE)
Assignee: CILIAN AG
C12N9/20A61K38/465C12Y301/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,584,920
App. No.
16/687,299
Granted
Feb 21, 2023
Kind
B2
Abstract

Disclosed is a combination of two or more lipase enzymes, and its use for treating a lipid digestion deficiency and/or a digestive disorder. At least one lipase enzyme has a pH optimum at an acidic pH value, while at least one other lipase enzyme has a pH optimum at an alkalic pH value.

Claims (9)

1. A pharmaceutical preparation comprising a combination of two or more lipase enzymes, wherein:

at least one lipase enzyme has a pH optimum at a pH value in the range of ≥1 and ≤6;

at least one other lipase enzyme has a pH optimum at a pH value in the range of ≥8 and ≤11; and

the two or more lipase enzymes comprise amino acid sequences having a sequence identity of at least 70% with any of SEQ ID Nos: 4-6.

2. The pharmaceutical preparation of claim 1 , wherein lipolytic activity of at least one lipase enzyme is determined with a Nixon Test or a titration test.

3. The pharmaceutical preparation of claim 1 , wherein at least one lipase enzyme is a lipase enzyme encoded, expressed and/or produced by an organism of the order ciliates.

4. The pharmaceutical preparation of claim 1 , wherein at least one lipase enzyme has been modified by site directed or random mutagenesis and subsequent selection.

5. The pharmaceutical preparation of claim 1 , wherein one lipase enzyme has a pH optimum at an acidic pH which occurs in the stomach of a mammal and wherein at least one other lipase enzyme has a pH optimum at an alkaline pH which occurs in the lower small intestine of a mammal.

6. The pharmaceutical preparation of claim 1 , wherein the two or more lipase enzymes comprise amino acid sequences selected from the group consisting of amino acid sequences having a sequence identity of at least 95% with any of SEQ ID Nos: 4-6.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2024
From: CILIAN AG
To: DERMAPHARM AKTIENGESELLSCHAFT
Reel/Frame 069743/0432 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 10, 2022
From: HARTMANN, MARCUS WOLF WILLIAM; ALDAG, INGO
To: CILIAN AG
Reel/Frame 061361/0697 →
Priority Claims (1)
GB 1501081 · Jan 22, 2015 · national
Continuity (2)
Division 15545583
Related Publication 20200071683A1 · Mar 5, 2020